Infinity Pharmaceuticals data positive, says RBC Capital

theflyonthewall.com

RBC Capital reports that data presented by Infinity (INFY) indicates that response rates for its chronic leukemia treatment have increased, while the durability of responses is strong. The firm believes that Infinity's leukemia treatment can be superior to Gilead's (GILD) product, and the firm keeps an Outperform rating on Infinity.

View Comments